X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The study will evaluate the safety, optimal dose and tumour response of the tigilanol tiglate and pembrolizumab combination in patients with late-stage unresectable melanoma, who have been previously exposed to immune checkpoint inhibitors.
Lead Product(s): Tigilanol Tiglate,Pembrolizumab
Therapeutic Area: Oncology Product Name: EBC-46
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The Phase I/II open label 'QBC46-H06' study is a dose escalation and expansion study with the primary objective of determining the maximum tolerated dose or maximum feasible dose of tigilanol tiglate, in combination with Keytruda® (pembrolizumab) therapy.
Lead Product(s): Tigilanol Tiglate,Pembrolizumab
Therapeutic Area: Oncology Product Name: EBC-46
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: QBiotics Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
